Details for Patent: 6,136,783
✉ Email this page to a colleague
Title: | Antifungal compositions |
Abstract: | The invention is a pharmaceutical composition for intravenous administration to a patient comprising a) a pharmaceutically effective amount of a compound having the formula ##STR1## and the pharmaceutically acceptable salts thereof; b) a pharmaceutically acceptable amount of an excipient such as a bulking agent effective to form a lyophilized cake; and c) a pharmaceutically acceptable amount of acetate buffer effective to provide a pH of between about 4 and 7. |
Inventor(s): | Neururkar; Maneesh J. (Lansdale, PA), Kaufman; Michael J. (New Hope, PA), Hunke; William A. (Harleysville, PA) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Filing Date: | Jun 15, 1999 |
Application Number: | 09/333,245 |
Claims: | 1. A method for treating an infection caused by Candida sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR9## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. 2. A method for treating an infection caused by Candida sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR10## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. 3. A method for treating an infection caused by Aspergillus sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR11## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. 4. A method for treating an infection caused by Aspergillus sp. in a patient which comprises administering intravenously to said patient an effective amount of a composition comprising 42 mg/ml of a compound having the formula ##STR12## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. 5. A method for treating or preventing an infection or condition caused by Pneumocystis carinii in a patient in need of such treatment or prevention which comprises administering intravenously to said patient a preventative or therapeutic amount of a composition comprising 42 mg/ml of a compound having the formula ##STR13## or a pharmaceutically acceptable salt thereof, 25 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. 6. A method for treating or preventing an infection or condition caused by Pneumocystis carinii in a patient in need of such treatment or prevention which comprises administering intravenously to said patient a preventative or therapeutic amount of a composition comprising 42 mg/ml of a compound having the formula ##STR14## or a pharmaceutically acceptable salt thereof, 50 mM of an acetate buffer, 30 mg/ml of sucrose, 20 mg/ml of mannitol, and water. |